Rapid and sensitive screening for CEBPA mutations in acute myeloid leukaemia

British Journal of Haematology

Volumn 143, Issue 2, 2008, Pages 230-239

  Benthaus, Tobias ^a   Schneider, Friederike ^a   Mellert, Gudrun ^a   Zellmeier, Evelyn ^a   Schneider, Stephanie ^a   Kakadia, Purvi M ^a,b   Hiddemann, Wolfgang ^a,b   Bohlander, Stefan K ^a,b   Feuring Buske, Michaela ^a,b   Braess, Jan ^a,b   Spiekermann, Karsten ^a,b   Dufour, Annika ^a  

^a UNIVERSITY OF MUNICH   (Germany)

^b INSTITUTE OF EPIDEMIOLOGY   (Germany)

Author keywords

Acute myeloid leukaemia; CCAAT enhancer binding protein alpha; Mutations; Normal karyotype acute myeloid leukaemia; Screening

Indexed keywords

CCAAT ENHANCER BINDING PROTEIN ALPHA;

ACCURACY; ACUTE GRANULOCYTIC LEUKEMIA; ADOLESCENT; ADULT; AGED; ARTICLE; CEBPA GENE; CONTROLLED STUDY; FRAGMENT LENGTH ANALYSIS; GENE; GENE MUTATION; GENETIC ANALYSIS; GENETIC SCREENING; HUMAN; HUMAN CELL; KARYOTYPE; MAJOR CLINICAL STUDY; MULTIPLEX POLYMERASE CHAIN REACTION; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROGNOSIS; REMISSION; SENSITIVITY AND SPECIFICITY; SEQUENCE ANALYSIS;

CCAAT-ENHANCER-BINDING PROTEIN-ALPHA; DNA MUTATIONAL ANALYSIS; DNA PRIMERS; HUMANS; LEUKEMIA, MYELOID, ACUTE; MUTATION; SENSITIVITY AND SPECIFICITY;

EID: 52649181031     PISSN: 00071048     EISSN: 13652141     Source Type: Journal    
DOI: 10.1111/j.1365-2141.2008.07328.x     Document Type: Article

References (38)

1. Baldus, C.D., Thiede, C., Soucek, S., Bloomfield, C.D., Thiel, E. Ehninger, G. (2006) BAALC expression and FLT3 internal tandem duplication mutations in acute myeloid leukemia patients with normal cytogenetics: prognostic implications. Journal of Clinical Oncology, 24, 790 797.
2. Baldus, C.D., Mrozek, K., Marcucci, G. Bloomfield, C.D. (2007) Clinical outcome of de novo acute myeloid leukaemia patients with normal cytogenetics is affected by molecular genetic alterations: a concise review. British Journal of Haematology, 137, 387 400.
3. Barjesteh van Waalwijk van Doorn-Khosrovani, S., Erpelinck, C., Meijer, J., van Oosterhoud, S., van Putten, W.L., Valk, P.J., Berna Beverloo, H., Tenen, D.G., Lowenberg, B. Delwel, R. (2003) Biallelic mutations in the CEBPA gene and low CEBPA expression levels as prognostic markers in intermediate-risk AML. Hematology Journal, 4, 31 40.
4. Bienz, M., Ludwig, M., Leibundgut, E.O., Mueller, B.U., Ratschiller, D., Solenthaler, M., Fey, M.F. Pabst, T. (2005) Risk assessment in patients with acute myeloid leukemia and a normal karyotype. Clinical Cancer Research, 11, 1416 1424.
5. Büchner, T., Berdel, W.E., Schoch, C., Haferlach, T., Serve, H.L., Kienast, J., Schnittger, S., Kern, W., Tchinda, J., Reichle, A., Lengfelder, E., Staib, P., Ludwig, W.D., Aul, C., Eimermacher, H., Balleisen, L., Sauerland, M.C., Heinecke, A., Wormann, B. Hiddemann, W. (2006) Double induction containing either two courses or one course of high-dose cytarabine plus mitoxantrone and postremission therapy by either autologous stem-cell transplantation or by prolonged maintenance for acute myeloid leukemia. Journal of Clinical Oncology, 24, 2480 2489.
6. Byrd, J.C., Mrozek, K., Dodge, R.K., Carroll, A.J., Edwards, C.G., Arthur, D.C., Pettenati, M.J., Patil, S.R., Rao, K.W., Watson, M.S., Koduru, P.R., Moore, J.O., Stone, R.M., Mayer, R.J., Feldman, E.J., Davey, F.R., Schiffer, C.A., Larson, R.A. Bloomfield, C.D. (2002) Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: results from Cancer and Leukemia Group B (CALGB 8461). Blood, 100, 4325 4336.
7. D'Alo, F., Johansen, L.M., Nelson, E.A., Radomska, H.S., Evans, E.K., Zhang, P., Nerlov, C. Tenen, D.G. (2003) The amino terminal and E2F interaction domains are critical for C/EBP alpha-mediated induction of granulopoietic development of hematopoietic cells. Blood, 102, 3163 3171.
8. Döhner, K., Schlenk, R.F., Habdank, M., Scholl, C., Rucker, F.G., Corbacioglu, A., Bullinger, L., Fröhling, S. Döhner, H. (2005) Mutant nucleophosmin (NPM1) predicts favorable prognosis in younger adults with acute myeloid leukemia and normal cytogenetics: interaction with other gene mutations. Blood, 106, 3740 3746.
9. Falini, B., Mecucci, C., Tiacci, E., Alcalay, M., Rosati, R., Pasqualucci, L., La Starza, R., Diverio, D., Colombo, E., Santucci, A., Bigerna, B., Pacini, R., Pucciarini, A., Liso, A., Vignetti, M., Fazi, P., Meani, N., Pettirossi, V., Saglio, G., Mandelli, F., Lo-Coco, F., Pelicci, P.G. Martelli, M.F. (2005) Cytoplasmic nucleophosmin in acute myelogenous leukemia with a normal karyotype. New England Journal of Medicine, 352, 254 266.
10. Friedman, A.D. McKnight, S.L. (1990) Identification of two polypeptide segments of CCAAT/enhancer-binding protein required for transcriptional activation of the serum albumin gene. Genes and Development, 4, 1416 1426.
11. Fröhling, S., Schlenk, R.F., Breitruck, J., Benner, A., Kreitmeier, S., Tobis, K., Döhner, H. Döhner, K. (2002) Prognostic significance of activating FLT3 mutations in younger adults (16 to 60 years) with acute myeloid leukemia and normal cytogenetics: a study of the AML Study Group Ulm. Blood, 100, 4372 4380.
12. Fröhling, S., Schlenk, R.F., Stolze, I., Bihlmayr, J., Benner, A., Kreitmeier, S., Tobis, K., Döhner, H. Döhner, K. (2004) CEBPA mutations in younger adults with acute myeloid leukemia and normal cytogenetics: prognostic relevance and analysis of cooperating mutations. Journal of Clinical Oncology, 22, 624 633.
13. Fuchs, O., Provaznikova, D., Kocova, M., Kostecka, A., Cvekova, P., Neuwirtova, R., Kobylka, P., Cermak, J., Brezinova, J., Schwarz, J., Markova, J., Salaj, P., Klamova, H., Maaloufova, J., Lemez, P., Novakova, L. Benesova, K. (2008) CEBPA polymorphisms and mutations in patients with acute myeloid leukemia, myelodysplastic syndrome, multiple myeloma and non-Hodgkin's lymphoma. Blood Cells, Molecules, and Diseases, 40, 401 405.
14. Gombart, A.F., Hofmann, W.K., Kawano, S., Takeuchi, S., Krug, U., Kwok, S.H., Larsen, R.J., Asou, H., Miller, C.W., Hoelzer, D. Koeffler, H.P. (2002) Mutations in the gene encoding the transcription factor CCAAT/enhancer binding protein alpha in myelodysplastic syndromes and acute myeloid leukemias. Blood, 99, 1332 1340.
15. Grimwade, D., Walker, H., Harrison, G., Oliver, F., Chatters, S., Harrison, C.J., Wheatley, K., Burnett, A.K. Goldstone, A.H. (2001) The predictive value of hierarchical cytogenetic classification in older adults with acute myeloid leukemia (AML): analysis of 1065 patients entered into the United Kingdom Medical Research Council AML11 trial. Blood, 98, 1312 1320.
16. Hasemann, M.S., Damgaard, I., Schuster, M.B., Theilgaard-Monch, K., Sorensen, A.B., Mrsic, A., Krugers, T., Ylstra, B., Pedersen, F.S., Nerlov, C. Porse, B.T. (2008) Mutation of C/EBPα predisposes to the development of myeloid leukemia in a retroviral insertional mutagenesis screen. Blood, 111, 4309 4321.
17. Kottaridis, P.D., Gale, R.E., Frew, M.E., Harrison, G., Langabeer, S.E., Belton, A.A., Walker, H., Wheatley, K., Bowen, D.T., Burnett, A.K., Goldstone, A.H. Linch, D.C. (2001) The presence of a FLT3 internal tandem duplication in patients with acute myeloid leukemia (AML) adds important prognostic information to cytogenetic risk group and response to the first cycle of chemotherapy: analysis of 854 patients from the United Kingdom Medical Research Council AML 10 and 12 trials. Blood, 98, 1752 1759.
18. Leroy, H., Roumier, C., Huyghe, P., Biggio, V., Fenaux, P. Preudhomme, C. (2005) CEBPA point mutations in hematological malignancies. Leukemia, 19, 329 334.
19. Liang, D.C., Shih, L.Y., Huang, C.F., Hung, I.J., Yang, C.P., Liu, H.C., Jaing, T.H., Wang, L.Y. Chang, W.H. (2005) CEBPalpha mutations in childhood acute myeloid leukemia. Leukemia, 19, 410 414.
20. Lin, L.I., Chen, C.Y., Lin, D.T., Tsay, W., Tang, J.L., Yeh, Y.C., Shen, H.L., Su, F.H., Yao, M., Huang, S.Y. Tien, H.F. (2005) Characterization of CEBPA mutations in acute myeloid leukemia: most patients with CEBPA mutations have biallelic mutations and show a distinct immunophenotype of the leukemic cells. Clinical Cancer Research, 11, 1372 1379.
21. Lin, L.I., Lin, T.C., Chou, W.C., Tang, J.L., Lin, D.T. Tien, H.F. (2006) A novel fluorescence-based multiplex PCR assay for rapid simultaneous detection of CEBPA mutations and NPM mutations in patients with acute myeloid leukemias. Leukemia, 20, 1899 1903.
22. Pabst, T., Mueller, B.U., Zhang, P., Radomska, H.S., Narravula, S., Schnittger, S., Behre, G., Hiddemann, W. Tenen, D.G. (2001) Dominant-negative mutations of CEBPA, encoding CCAAT/enhancer binding protein-alpha (C/EBPalpha), in acute myeloid leukemia. Nature Genetics, 27, 263 270.
23. Preudhomme, C., Sagot, C., Boissel, N., Cayuela, J.M., Tigaud, I., de Botton, S., Thomas, X., Raffoux, E., Lamandin, C., Castaigne, S., Fenaux, P. Dombret, H. (2002) Favorable prognostic significance of CEBPA mutations in patients with de novo acute myeloid leukemia: a study from the Acute Leukemia French Association (ALFA). Blood, 100, 2717 2723.
24. Renneville, A., Roumier, C., Biggio, V., Nibourel, O., Boissel, N., Fenaux, P. Preudhomme, C. (2008) Cooperating gene mutations in acute myeloid leukemia: a review of the literature. Leukemia, 22, 915 931.
25. Resende, C., Regalo, G., Duraes, C., Carneiro, F. Machado, J.C. (2007) Genetic changes of CEBPA in cancer: mutations or polymorphisms? Journal of Clinical Oncology, 25, 2493 2494 author reply 2494-2495.
26. Schlenk, R.F., Döhner, K., Krauter, J., Fröhling, S., Corbacioglu, A., Bullinger, L., Habdank, M., Spath, D., Morgan, M., Benner, A., Schlegelberger, B., Heil, G., Ganser, A. Döhner, H. (2008) Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia. New England Journal of Medicine, 358, 1909 1918.
27. Schnittger, S., Schoch, C., Dugas, M., Kern, W., Staib, P., Wuchter, C., Loffler, H., Sauerland, C.M., Serve, H., Büchner, T., Haferlach, T. Hiddemann, W. (2002) Analysis of FLT3 length mutations in 1003 patients with acute myeloid leukemia: correlation to cytogenetics, FAB subtype, and prognosis in the AMLCG study and usefulness as a marker for the detection of minimal residual disease. Blood, 100, 59 66.
28. Schnittger, S., Schoch, C., Kern, W., Mecucci, C., Tschulik, C., Martelli, M.F., Haferlach, T., Hiddemann, W. Falini, B. (2005) Nucleophosmin gene mutations are predictors of favorable prognosis in acute myelogenous leukemia with a normal karyotype. Blood, 106, 3733 3739.
29. Schwieger, M., Lohler, J., Fischer, M., Herwig, U., Tenen, D.G. Stocking, C. (2004) A dominant-negative mutant of C/EBPalpha, associated with acute myeloid leukemias, inhibits differentiation of myeloid and erythroid progenitors of man but not mouse. Blood, 103, 2744 2752.
30. Shih, L.Y., Liang, D.C., Huang, C.F., Wu, J.H., Lin, T.L., Wang, P.N., Dunn, P., Kuo, M.C. Tang, T.C. (2006) AML patients with CEBPalpha mutations mostly retain identical mutant patterns but frequently change in allelic distribution at relapse: a comparative analysis on paired diagnosis and relapse samples. Leukemia, 20, 604 609.
31. Slovak, M.L., Kopecky, K.J., Cassileth, P.A., Harrington, D.H., Theil, K.S., Mohamed, A., Paietta, E., Willman, C.L., Head, D.R., Rowe, J.M., Forman, S.J. Appelbaum, F.R. (2000) Karyotypic analysis predicts outcome of preremission and postremission therapy in adult acute myeloid leukemia: a Southwest Oncology Group/Eastern Cooperative Oncology Group Study. Blood, 96, 4075 4083.
32. Snaddon, J., Smith, M.L., Neat, M., Cambal-Parrales, M., Dixon-McIver, A., Arch, R., Amess, J.A., Rohatiner, A.Z., Lister, T.A. Fitzgibbon, J. (2003) Mutations of CEBPA in acute myeloid leukemia FAB types M1 and M2. Genes, Chromosomes and Cancer, 37, 72 78.
33. Thiede, C., Steudel, C., Mohr, B., Schaich, M., Schakel, U., Platzbecker, U., Wermke, M., Bornhauser, M., Ritter, M., Neubauer, A., Ehninger, G. Illmer, T. (2002) Analysis of FLT3-activating mutations in 979 patients with acute myelogenous leukemia: association with FAB subtypes and identification of subgroups with poor prognosis. Blood, 99, 4326 4335.
34. Thiede, C., Koch, S., Creutzig, E., Steudel, C., Illmer, T., Schaich, M. Ehninger, G. (2006) Prevalence and prognostic impact of NPM1 mutations in 1485 adult patients with acute myeloid leukemia (AML). Blood, 107, 4011 4020.
35. Verhaak, R.G., Goudswaard, C.S., van Putten, W., Bijl, M.A., Sanders, M.A., Hugens, W., Uitterlinden, A.G., Erpelinck, C.A., Delwel, R., Lowenberg, B. Valk, P.J. (2005) Mutations in nucleophosmin (NPM1) in acute myeloid leukemia (AML): association with other gene abnormalities and previously established gene expression signatures and their favorable prognostic significance. Blood, 106, 3747 3754.
36. Vinson, C.R., Sigler, P.B. McKnight, S.L. (1989) Scissors-grip model for DNA recognition by a family of leucine zipper proteins. Science, 246, 911 916.
37. Whitman, S.P., Archer, K.J., Feng, L., Baldus, C., Becknell, B., Carlson, B.D., Carroll, A.J., Mrozek, K., Vardiman, J.W., George, S.L., Kolitz, J.E., Larson, R.A., Bloomfield, C.D. Caligiuri, M.A. (2001) Absence of the wild-type allele predicts poor prognosis in adult de novo acute myeloid leukemia with normal cytogenetics and the internal tandem duplication of FLT3: a cancer and leukemia group B study. Cancer Research, 61, 7233 7239.
38. Wouters, B.J., Louwers, I., Valk, P.J., Lowenberg, B. Delwel, R. (2007) A recurrent in-frame insertion in a CEBPA transactivation domain is a polymorphism rather than a mutation that does not affect gene expression profiling-based clustering of AML. Blood, 109, 389 390.